Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarafem patent upheld

Executive Summary

D.C. federal appeals court upholds Sarafem (fluoxetine) use patent as valid and infringed by Teva's ANDA in a July 13 FDL-1ruling. The premenstrual dysphoric disorder product, a repackaged version of Prozac, was launched by Lilly in August 2000; the company divested it to Galen/Warner Chilcott in 2002 (1"The Pink Sheet" Dec.16, 2002, p. 34). The appellate court rejected Teva's arguments that the Indianapolis district court erred by construing the patent claim to include dosing regimens "that go on continuously." The court also disagreed with Teva's argument that the lower court improperly ruled the patent invalid for reasons of obviousness (2"The Pink Sheet" Aug. 23, 2004, In Brief)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel